Back to search results

SLIMM 2 Study for Chronic Kidney Disease and Obesity

The SLIMM 2 study is looking at ways to help people with chronic kidney disease and obesity reduce prolonged sitting. Researchers are testing different approaches: the SLIMM behavioral intervention (replacing sitting with light walking and taking standing breaks), standard resistance training, and guided resistance training. They are also studying an oral medication called semaglutide, or a placebo (inactive pill). To join, you need to be at least 20 years old, have a specific range of kidney function (eGFR 20 to <60 mL/min/1.73m^2), be able to do resistance training, and have a smartphone or similar device. The main goal is to see how much the average time spent sitting changes over 12 months. This study is currently unclear about its recruitment status.

Study design
This is an interventional study planning to enroll 156 participants. It involves different behavioral interventions and a drug intervention with either semaglutide or a placebo.
What's involved
Participants will engage in behavioral interventions like light walking, standing breaks, or resistance training. Those in the drug intervention will take oral semaglutide or placebo tablets for nine months.
Compensation
Not stated in the trial record.
Follow-up
The study measures changes in sedentary duration up to 12 months from randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05173714

Sit Less, Interact and Move More (SLIMM) 2 Study

Recruiting
PHASE2Ages 20+InterventionalTreatment
Srinvasan Beddhu
~156 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:SLIMMStandard Resistance TrainingGuided Resistance TrainingPlaceboSemaglutide

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization
Measured over Randomization to 12 Months

Conditions

Chronic Kidney Diseases
Obesity

Explore related trials

Chronic Kidney DiseaseObesity

Where it's being run

2 sites across 2 states
California1
Utah1

Study leadership

  • Srinivasan Beddhu, M.D. · PRINCIPAL_INVESTIGATOR · University of Utah

Who to contact

Amara Sarwal, M.D.
[email protected]
801-585-9815
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
Able to perform resistance training
Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Exclusion

Type 1 Diabetes
History of gastroparesis or paralytic ileus
At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
Previous bariatric surgery
Medical condition likely to limit survival to less than 1 year
Anticipated start of dialysis or kidney transplantation within 6 months
Any factors judged by the investigator or study team to likely limit adherence to interventions
Vulnerable populations- pregnant or incarcerated
Enrolled in interventional trials using drugs or devices
Not able to undergo informed consent
Recent hospitalizations or major interventional procedures done within the past 60 days
Known or suspected hypersensitivity to tegaderm
Use of any GLP-1 receptor agonist within 30 days prior to screening
Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
Presence of metastatic cancer
Current use of mobility aid(s)
Living in the same household of a participant already enrolled in the study

What this trial measures

  • Average Change in Sedentary Duration at Months 8, 10 and 12 from RandomizationRandomization to 12 Months

    The primary analysis will provide estimates and confidence intervals for the three arms comparisons of changes in sedentary duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups that constitute the co-primary comparisons under the study design